Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

YD DIAGNOSTICS

Specializes in the manufacture of total in vitro diagnostic products. Product applications include urinalysis, blood ... read more Featured Products: More products

Download Mobile App




Semiquantitative Urine Dipstick Evaluated for Microalbuminuria Screening

By LabMedica International staff writers
Posted on 21 Aug 2014
The urine microalbumin test is used as a screening test for the diagnosis of renal complications in diseases, such as diabetic nephropathy, cardiovascular disease, and hypertension.

A urine dipstick test that can conveniently and semiquantitatively measure concentrations of urine microalbumin and creatinine as well as the albumin/creatinine ratio (ACR) has been developed and the diagnostic performance of the dipstick evaluated.

Laboratory scientists at the University of Ulsan College of Medicine (Seoul, Republic of Korea) and their colleagues randomly selected 1,040 urine specimens that had been sent for ACR tests from July 1, 2011, to August 31, 2011. Albumin and creatinine tests were performed using random, midstream spot urine samples, and all tests were completed within two hours of urine collection. The results of the dipstick tests were compared with measurements obtained by a quantitative analyzer.

The newly introduced semiquantitative urine dipstick evaluated was the URiSCAN Super cassette ACR (URiSuper-ACR, YD Diagnostics Corp.; Yongin-si, Republic of Korea). Detection of albumin and creatinine in the URiSuper-ACR were performed using the dye-binding and metal complex methods, respectively. The color change made by the reaction was measured by the URiSCAN Super Plus reflectance meter. The Cobas Integra 800 quantitative analyzer (Roche Diagnostics; Rotkreuz Switzerland), which uses immunoturbidometric and the Jaffe-kinetic method, was used as the comparison methodology.

The URiSuper-ACR test showed 88.8% and 86.3% sensitivity and 90.1% and 93.8% specificity for albumin concentration and ACR, respectively and showed 91.1% and 92.6% positive predictive values. The concordance rate between URiSuper-ACR and Cobas Integra quantitative method for albumin and creatinine concentration within the same category were 78.4% and 67.1%, respectively, and for the ±1 category were 98.8% and 99.5%, respectively. For ACR, an 80.0% concordance rate was seen within the same category.

The authors concluded that in their evaluation study on a heterogeneous patient group, the URiSuper-ACR showed good diagnostic performance, such as excellent sensitivity, specificity, concordance rate with quantitative method, linearity, and precision, and this method could be used as an effective screening tool for the detection of microalbuminuria in clinical laboratories. The study was published in the July 2014 issue of the Journal of Clinical Laboratory Analysis.

Related Links:

University of Ulsan College of Medicine
YD Diagnostics Corp. 
Roche Diagnostics



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.